Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Change in Receivables (2019 - 2025)

AVITA Medical's Change in Receivables history spans 7 years, with the latest figure at -$81000.0 for Q4 2025.

  • For Q4 2025, Change in Receivables rose 94.56% year-over-year to -$81000.0; the TTM value through Dec 2025 reached $3.6 million, up 187.65%, while the annual FY2025 figure was $3.6 million, 187.65% up from the prior year.
  • Change in Receivables reached -$81000.0 in Q4 2025 per RCEL's latest filing, down from $2.3 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $2.8 million in Q1 2021 to a low of -$3.5 million in Q4 2023.
  • Average Change in Receivables over 5 years is -$68888.9, with a median of $132000.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: soared 333.64% in 2021, then crashed 527.39% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $345000.0 in 2021, then skyrocketed by 201.16% to $1.0 million in 2022, then crashed by 434.46% to -$3.5 million in 2023, then surged by 57.15% to -$1.5 million in 2024, then skyrocketed by 94.56% to -$81000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCEL's Change in Receivables are -$81000.0 (Q4 2025), $2.3 million (Q3 2025), and $1.6 million (Q2 2025).